Zhifeng Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhifeng Qi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Shuhua Yuan
Department of Hyperbaric Oxygen, Beijing Chaoyang Hospital Capital Medical University Beijing China
10 shared publicationsKe Jian Liu
Department of Pathology Renaissance School of Medicine, Stony Brook University Stony Brook New York USA
6 shared publications- Xunming Ji
Capital Medical University
6 shared publications Wenjuan Shi
Department of Neurology, Cerebrovascular Diseases Research Institute Xuanwu Hospital of Capital Medical University Beijing China
5 shared publicationsXunming Ji
Cerebrovascular Diseases Research Institute, Xuanwu Hospital of Capital Medical University, Beijing 100053, China; Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
5 shared publicationsChengbei Hou
Center for Evidence-Based Medicine, Xuanwu Hospital of Capital Medical University, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70885
Zinc Overload in Microvessels Contributes to Blood–Brain Barrier Disruption by Activating the JAK2 Pathway After Cerebral Ischemia/Reperfusion
Aims: Stroke is one of the leading causes of adult disability and death worldwide. Inflammation‐induced microvascular dysfunction and increased blood–brain barrier (BBB) permeability are major contributors to cerebral ischemia/reperfusion (I/R) injury. Previous studies have shown that zinc accumulation in microvessels contributes to BBB disruption following I/R. However, the mechanisms linking zinc accumulation to microvascular inflammation remain poorly understood. Methods: We investigated whether the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) inflammatory pathway mediates microvascular zinc overload‐induced BBB damage, using the model of I/R rats, endothelial cells and neuron‐specific zinc transporter 3 knockout (ZnT3‐cKO) mice. Results: Our findings in I/R rats and endothelial cells revealed that zinc accumulation in microvessels activated JAK2, promoting mitochondrial translocation of phosphorylated STAT3 (p‐STAT3) and exacerbating BBB disruption. These effects were significantly suppressed by zinc chelation. Furthermore, inhibition of neuronal zinc release in ZnT3‐cKO mice markedly reduced zinc accumulation and JAK2 activation in ischemic microvessels. ZnT3 knockout also prevented mitochondrial translocation of p‐STAT3, attenuated mitochondrial dysfunctions, and abolished zinc overload‐induced BBB permeability following I/R. Conclusion: This study suggests that zinc accumulation in microvessels contributes to I/R‐induced BBB damage through JAK2/STAT3 signaling and highlights a potential therapeutic target for preserving vascular integrity after stroke.
- 16 April 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (4) , e70885
Open AccessZinc Overload in Microvessels Contributes to Blood–Brain Barrier Disruption by Activating the JAK2 Pathway After Cerebral Ischemia/Reperfusion
Aims: Stroke is one of the leading causes of adult disability and death worldwide. Inflammation‐induced microvascular dysfunction and increased blood–brain barrier (BBB) permeability are major contributors to cerebral ischemia/reperfusion (I/R) injury. Previous studies have shown that zinc accumulation in microvessels contributes to BBB disruption following I/R. However, the mechanisms linking zinc accumulation to microvascular inflammation remain poorly understood. Methods: We investigated whether the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) inflammatory pathway mediates microvascular zinc overload‐induced BBB damage, using the model of I/R rats, endothelial cells and neuron‐specific zinc transporter 3 knockout (ZnT3‐cKO) mice. Results: Our findings in I/R rats and endothelial cells revealed that zinc accumulation in microvessels activated JAK2, promoting mitochondrial translocation of phosphorylated STAT3 (p‐STAT3) and exacerbating BBB disruption. These effects were significantly suppressed by zinc chelation. Furthermore, inhibition of neuronal zinc release in ZnT3‐cKO mice markedly reduced zinc accumulation and JAK2 activation in ischemic microvessels. ZnT3 knockout also prevented mitochondrial translocation of p‐STAT3, attenuated mitochondrial dysfunctions, and abolished zinc overload‐induced BBB permeability following I/R. Conclusion: This study suggests that zinc accumulation in microvessels contributes to I/R‐induced BBB damage through JAK2/STAT3 signaling and highlights a potential therapeutic target for preserving vascular integrity after stroke.
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e041825
Normobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation
Background: Inflammatory response is an important pathological and physiological mechanism in the occurrence and development of acute ischemic stroke. This study investigated the effects of normobaric hyperoxia on the inflammatory response in acute ischemic stroke and explored the role of inflammation in stroke‐induced brain injury. Methods: This secondary analysis of the OPENS (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, included 86 acute ischemic stroke patients with anterior circulation large vessel occlusion: 43 received normobaric hyperoxia (10 L/min, 100% oxygen for 4 hours) with endovascular thrombectomy, and 43 received endovascular thrombectomy alone. Inflammatory markers were measured at different time points (admission, 24 hours, 7 days), and National Institutes of Health Stroke Scale score and cerebral infarction volume were also recorded. The main outcome measures were serum CRP (C‐reactive protein) levels, peripheral blood leukocyte count, neutrophil count, and neutrophil‐to‐lymphocyte ratio. Correlation analysis was used to analyze the relationship between inflammatory markers and stroke. Results: The results showed that the normobaric hyperoxia group had significantly lower levels of inflammatory markers compared with the control group at 24 hours ( P <0.05). Early correlation analysis (within 24 hours) showed a significant positive association between 24‐hour inflammatory marker levels and early neurological function scores (National Institutes of Health Stroke Scale) as well as early infarct volume (assessed at 24–48 hours). Conclusions: Normobaric hyperoxia attenuates early postthrombectomy inflammation, as evidenced by reduced CRP, neutrophil counts, and neutrophil‐to‐lymphocyte ratio. These inflammation markers were significantly associated with acute stroke severity and infarct volume. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03620370.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e041825
Open AccessNormobaric Hyperoxia in Patients With Acute Stroke: Enhancing Neuroprotection Through Inhibition of Inflammation
Background: Inflammatory response is an important pathological and physiological mechanism in the occurrence and development of acute ischemic stroke. This study investigated the effects of normobaric hyperoxia on the inflammatory response in acute ischemic stroke and explored the role of inflammation in stroke‐induced brain injury. Methods: This secondary analysis of the OPENS (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) trial, included 86 acute ischemic stroke patients with anterior circulation large vessel occlusion: 43 received normobaric hyperoxia (10 L/min, 100% oxygen for 4 hours) with endovascular thrombectomy, and 43 received endovascular thrombectomy alone. Inflammatory markers were measured at different time points (admission, 24 hours, 7 days), and National Institutes of Health Stroke Scale score and cerebral infarction volume were also recorded. The main outcome measures were serum CRP (C‐reactive protein) levels, peripheral blood leukocyte count, neutrophil count, and neutrophil‐to‐lymphocyte ratio. Correlation analysis was used to analyze the relationship between inflammatory markers and stroke. Results: The results showed that the normobaric hyperoxia group had significantly lower levels of inflammatory markers compared with the control group at 24 hours ( P <0.05). Early correlation analysis (within 24 hours) showed a significant positive association between 24‐hour inflammatory marker levels and early neurological function scores (National Institutes of Health Stroke Scale) as well as early infarct volume (assessed at 24–48 hours). Conclusions: Normobaric hyperoxia attenuates early postthrombectomy inflammation, as evidenced by reduced CRP, neutrophil counts, and neutrophil‐to‐lymphocyte ratio. These inflammation markers were significantly associated with acute stroke severity and infarct volume. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03620370.
- Open Access
- 26 March 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (3) , e70321
The Association of Serum Biomarkers With Symptomatic Hemorrhagic Transformation in Acute Ischemic Stroke Patients: A Combined Retrospective and Prospective Study
Background and Purpose: Symptomatic intracranial hemorrhage transformation (s‐HT) is a serious complication of ischemic stroke, leading to early neurological deterioration and poor prognosis. It is an urgent problem to timely and effectively identify high‐risk patients with s‐HT at the early stage of stroke. However, so far, there are no effective clinical detection methods or measures. Therefore, the present study aimed to explore novel blood biomarkers related to s‐HT.Methods: This study includes two parts: a retrospective study and a prospective cohort study. In the first part, s‐HT patients were screened (n = 18), and non‐s‐HTs (n = 128) were selected from the same period of case patients in the retrospective study cohort. The baseline blood samples were obtained within 30 min of admission, and the levels of 92 proteins related to cerebrovascular diseases were detected using the Olink proteomics technology. Multivariate logistic regression and receiver operating characteristic curves were used to analyze the relationship between serum biomarker levels and s‐HT. In the second part, s‐HT patients (n = 28) and non‐s‐HTs (n = 130) were selected from a prospective study cohort, which met the same criteria for inclusion and exclusion. Enzyme‐linked immunosorbent assay (ELISA) was used to measure the levels of potential biomarker(s) in serum screened from the first part to confirm its/their association(s) with s‐HT.Results: Olink assay showed that patients with s‐HT had lower von Willebrand factor (vWF) levels and higher osteoprotegerin, phospholipase C, human insulin‐like growth factor binding protein‐7, matrix metalloproteinase‐2, galectin‐4, spondin‐1 than non‐s‐HTs (n = 128) (p < 0.005) in a retrospective study cohort. Principal component (PC) and factor analysis showed that the seven biomarkers could explain 62.76% of the variance in the Olink biomarker set, and vWF was a main loading factor in PC2. Multivariate regression analysis showed that a low level of vWF was an independent risk factor (p < 0.05) for s‐HT after adjusting for potential confounders. ELISA test results showed that s‐HT patients had a significantly lower vWF levels than the non‐s‐HT group (26.57 [13.64–37.18] vs. 42.00 [26.02–55.52] ng/mL, p < 0.001) in the prospective study cohort. Incorporating vWF into the clinical risk factors significantly improved the accuracy of predicting s‐HT (area under the curve [AUC, 0.731 vs. 0.641, p < 0.001], [AUC, 0.747 vs. 0.560, p < 0.001]) compared to a model employing only clinical risk factors in both study cohorts.Conclusion: Through the use of a combined retrospective and prospective study, vWF might be a novel blood biomarker for predicting s‐HT occurrence in ischemic stroke patients.
- 26 March 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (3) , e70321
Open AccessThe Association of Serum Biomarkers With Symptomatic Hemorrhagic Transformation in Acute Ischemic Stroke Patients: A Combined Retrospective and Prospective Study
Background and Purpose: Symptomatic intracranial hemorrhage transformation (s‐HT) is a serious complication of ischemic stroke, leading to early neurological deterioration and poor prognosis. It is an urgent problem to timely and effectively identify high‐risk patients with s‐HT at the early stage of stroke. However, so far, there are no effective clinical detection methods or measures. Therefore, the present study aimed to explore novel blood biomarkers related to s‐HT.Methods: This study includes two parts: a retrospective study and a prospective cohort study. In the first part, s‐HT patients were screened (n = 18), and non‐s‐HTs (n = 128) were selected from the same period of case patients in the retrospective study cohort. The baseline blood samples were obtained within 30 min of admission, and the levels of 92 proteins related to cerebrovascular diseases were detected using the Olink proteomics technology. Multivariate logistic regression and receiver operating characteristic curves were used to analyze the relationship between serum biomarker levels and s‐HT. In the second part, s‐HT patients (n = 28) and non‐s‐HTs (n = 130) were selected from a prospective study cohort, which met the same criteria for inclusion and exclusion. Enzyme‐linked immunosorbent assay (ELISA) was used to measure the levels of potential biomarker(s) in serum screened from the first part to confirm its/their association(s) with s‐HT.Results: Olink assay showed that patients with s‐HT had lower von Willebrand factor (vWF) levels and higher osteoprotegerin, phospholipase C, human insulin‐like growth factor binding protein‐7, matrix metalloproteinase‐2, galectin‐4, spondin‐1 than non‐s‐HTs (n = 128) (p < 0.005) in a retrospective study cohort. Principal component (PC) and factor analysis showed that the seven biomarkers could explain 62.76% of the variance in the Olink biomarker set, and vWF was a main loading factor in PC2. Multivariate regression analysis showed that a low level of vWF was an independent risk factor (p < 0.05) for s‐HT after adjusting for potential confounders. ELISA test results showed that s‐HT patients had a significantly lower vWF levels than the non‐s‐HT group (26.57 [13.64–37.18] vs. 42.00 [26.02–55.52] ng/mL, p < 0.001) in the prospective study cohort. Incorporating vWF into the clinical risk factors significantly improved the accuracy of predicting s‐HT (area under the curve [AUC, 0.731 vs. 0.641, p < 0.001], [AUC, 0.747 vs. 0.560, p < 0.001]) compared to a model employing only clinical risk factors in both study cohorts.Conclusion: Through the use of a combined retrospective and prospective study, vWF might be a novel blood biomarker for predicting s‐HT occurrence in ischemic stroke patients.
- Open Access
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Enhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 18 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e036474
Open AccessEnhancing Blood–Brain Barrier Integrity in Patients With Acute Ischemic Stroke Via Normobaric Hyperoxia
BACKGROUND: Recent advancements in animal studies have demonstrated the potential of normobaric hyperoxia (NBO) as a promising intervention for preserving the integrity of the blood–brain barrier (BBB). However, there is still limited understanding of the effects of NBO on BBB function in patients with clinical stroke. Therefore, the objective of this study was to investigate the efficacy of NBO therapy in attenuating BBB damage and reducing brain injury in individuals undergoing endovascular treatment (EVT) for acute stroke. METHODS AND RESULTS: This study enrolled patients from the OPENS‐1 (Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke) study, with 43 patients receiving NBO combined with EVT and 43 patients receiving EVT alone. The main outcome measures included serum levels of occludin, MMP‐9 (matrix metalloproteinase‐9), NSE (neuron‐specific enolase), and S100b at 24 hours and 7 days, as well as the intracranial extravasation rate at 24 hours. Serum markers were assessed using ELISA, and intracranial contrast extravasation was visualized using dual‐energy computed tomography scan. We analyzed a total of 86 patients and found that the 24‐hour serum markers levels of BBB damage and brain injury were significantly lower in the group receiving NBO therapy combined with EVT compared with the group receiving EVT alone. Similarly, at 7 days, the levels of occludin, MMP‐9, and NSE were lower in the NBO+EVT group. We also found that the 24‐hour serum levels of occludin and MMP‐9 were correlated with intracranial contrast extravasation. Additionally, the incidence of intracranial contrast extravasation was lower in the NBO+EVT group compared with the EVT group (35.9% versus 60.5%, P =0.031). CONCLUSIONS: This study offers valuable insights into the positive impact of NBO on maintaining BBB integrity and reducing brain injury in patients with acute stroke undergoing EVT.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1468-1476
Normobaric Hyperoxia Combined With Endovascular Treatment Based on Temporal Gradient: A Dose-Escalation Study
BACKGROUND: Normobaric hyperoxia (NBO) has neuroprotective effects in acute ischemic stroke. Thus, we aimed to identify the optimal NBO treatment duration combined with endovascular treatment. METHODS: This is a single-center, randomized controlled, open-label, blinded-end point dose-escalation clinical trial. Patients with acute ischemic stroke who had an indication for endovascular treatment at Tianjin Huanhu Hospital were randomly assigned to 4 groups (1:1 ratio) based on NBO therapy duration: (1) control group (1 L/min oxygen for 4 hours); (2) NBO-2h group (10 L/min for 2 hours); (3) NBO-4h group (10 L/min for 4 hours); and (4) NBO-6h group (10 L/min for 6 hours). The primary outcome was cerebral infarction volume at 72 hours after randomization using an intention-to-treat analysis model. The primary safety outcome was the 90-day mortality rate. RESULTS: Between June 2022 and September 2023, 100 patients were randomly assigned to the following groups: control group (n=25), NBO-2h group (n=25), NBO-4h group (n=25), and NBO-6h group (n=25). The 72-hour cerebral infarct volumes were 39.4±34.3 mL, 30.6±30.1 mL, 19.7±15.4 mL, and 22.6±22.4 mL, respectively ( P =0.013). The NBO-4h and NBO-6h groups both showed statistically significant differences (adjusted P values: 0.011 and 0.027, respectively) compared with the control group. Compared with the control group, both the NBO-4h and NBO-6h groups showed significant differences ( P <0.05) in the National Institutes of Health Stroke Scale scores at 24 hours, 72 hours, and 7 days, as well as in the change of the National Institutes of Health Stroke Scale scores from baseline to 24 hours. Additionally, there were no significant differences among the 4 groups in terms of 90-day mortality rate, symptomatic intracranial hemorrhage, early neurological deterioration, or severe adverse events. CONCLUSIONS: The effectiveness of NBO therapy was associated with oxygen administration duration. Among patients with acute ischemic stroke who underwent endovascular treatment, NBO therapy for 4 and 6 hours was found to be more effective. Larger-scale multicenter studies are needed to validate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05404373.
- 28 February 2024
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 16 (3)
Contribution of zinc accumulation to ischemic brain injury and its mechanisms about oxidative stress, inflammation, and autophagy: an update
Ischemic stroke is a leading cause of death and disability worldwide, and presently, there is no effective neuroprotective therapy. Zinc is an essential trace element that plays important physiological roles in the central nervous system. Free zinc concentration is tightly regulated by zinc-related proteins in the brain under normal conditions. Disruption of zinc homeostasis, however, has been found to play an important role in the mechanism of brain injury following ischemic stroke. A large of free zinc releases from storage sites after cerebral ischemia, which affects the functions and survival of nerve cells, including neurons, astrocytes, and microglia, resulting in cell death. Ischemia-triggered intracellular zinc accumulation also disrupts the function of blood–brain barrier via increasing its permeability, impairing endothelial cell function, and altering tight junction levels. Oxidative stress and neuroinflammation have been reported to be as major pathological mechanisms in cerebral ischemia/reperfusion injury. Studies have showed that the accumulation of intracellular free zinc could impair mitochondrial function to result in oxidative stress, and form a positive feedback loop between zinc accumulation and reactive oxygen species production, which leads to a series of harmful reactions. Meanwhile, elevated intracellular zinc leads to neuroinflammation. Recent studies also showed that autophagy is one of the important mechanisms of zinc toxicity after ischemic injury. Interrupting the accumulation of zinc will reduce cerebral ischemia injury and improve neurological outcomes. This review summarizes the role of zinc toxicity in cellular and tissue damage following cerebral ischemia, focusing on the mechanisms about oxidative stress, inflammation, and autophagy.
- 28 February 2024
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 16 (3)
Contribution of zinc accumulation to ischemic brain injury and its mechanisms about oxidative stress, inflammation, and autophagy: an update
Ischemic stroke is a leading cause of death and disability worldwide, and presently, there is no effective neuroprotective therapy. Zinc is an essential trace element that plays important physiological roles in the central nervous system. Free zinc concentration is tightly regulated by zinc-related proteins in the brain under normal conditions. Disruption of zinc homeostasis, however, has been found to play an important role in the mechanism of brain injury following ischemic stroke. A large of free zinc releases from storage sites after cerebral ischemia, which affects the functions and survival of nerve cells, including neurons, astrocytes, and microglia, resulting in cell death. Ischemia-triggered intracellular zinc accumulation also disrupts the function of blood–brain barrier via increasing its permeability, impairing endothelial cell function, and altering tight junction levels. Oxidative stress and neuroinflammation have been reported to be as major pathological mechanisms in cerebral ischemia/reperfusion injury. Studies have showed that the accumulation of intracellular free zinc could impair mitochondrial function to result in oxidative stress, and form a positive feedback loop between zinc accumulation and reactive oxygen species production, which leads to a series of harmful reactions. Meanwhile, elevated intracellular zinc leads to neuroinflammation. Recent studies also showed that autophagy is one of the important mechanisms of zinc toxicity after ischemic injury. Interrupting the accumulation of zinc will reduce cerebral ischemia injury and improve neurological outcomes. This review summarizes the role of zinc toxicity in cellular and tissue damage following cerebral ischemia, focusing on the mechanisms about oxidative stress, inflammation, and autophagy.
- Open Access
- 18 September 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (3)
Association of serum occludin levels and perihematomal edema volumes in intracranial hemorrhage patients
Background and Purpose: Perihematomal edema (PHE) is one of the severe secondary damages following intracranial hemorrhage (ICH). Studies showed that blood–brain barrier (BBB) injury contributes to the development of PHE. Previous studies showed that occludin protein is a potential biomarker of BBB injury. In the present study, we investigated whether the levels of serum occludin on admission are associated with PHE volumes in ICH patients.Methods: This cross‐sectional study included 90ICH patients and 32 healthy controls.The volumes of hematoma and PHE were assessed using non‐contrast cranial CT within 30 min of admission. Blood samples were drawn on admission, and the levels of baseline serum occludin were detected using enzyme‐linked immunosorbent assay. Partial correlation analysis and multiple linear regression analysis were performed to evaluate the association between serum occludin levels and PHE volumes in ICH patients.Results: The serum occludin levels in ICH patients were much higher than health controls (median 0.27 vs. 0.13 ng/mL, p < 0.001). At admission, 34 ICH patients (37.78%) had experienced a severe PHE (≥30 mL), and their serum occludin levels were higher compared to those with mild PHE (p < 0.001). The area under the receiver operating characteristics curve (ROC) of serum occludin level in predicting severe PHE was 0.747 (95% confidence interval CI 0.644–0.832, p < 0.001). There was a significant positive correlation between serum occludin levels and PHE volumes (partial correlation r = 0.675, p < 0.001). Multiple linear regression analysis showed that serum occludin levels remained independently associated with the PHE volumes after adjusting other confounding factors.Conclusion: The present study showed that serum occludin levels at admission were independently correlated with PHE volumes in ICH patients, which may provide a biomarker indicating PHE volume change.
- 18 September 2023
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (3)
Open AccessAssociation of serum occludin levels and perihematomal edema volumes in intracranial hemorrhage patients
Background and Purpose: Perihematomal edema (PHE) is one of the severe secondary damages following intracranial hemorrhage (ICH). Studies showed that blood–brain barrier (BBB) injury contributes to the development of PHE. Previous studies showed that occludin protein is a potential biomarker of BBB injury. In the present study, we investigated whether the levels of serum occludin on admission are associated with PHE volumes in ICH patients.Methods: This cross‐sectional study included 90ICH patients and 32 healthy controls.The volumes of hematoma and PHE were assessed using non‐contrast cranial CT within 30 min of admission. Blood samples were drawn on admission, and the levels of baseline serum occludin were detected using enzyme‐linked immunosorbent assay. Partial correlation analysis and multiple linear regression analysis were performed to evaluate the association between serum occludin levels and PHE volumes in ICH patients.Results: The serum occludin levels in ICH patients were much higher than health controls (median 0.27 vs. 0.13 ng/mL, p < 0.001). At admission, 34 ICH patients (37.78%) had experienced a severe PHE (≥30 mL), and their serum occludin levels were higher compared to those with mild PHE (p < 0.001). The area under the receiver operating characteristics curve (ROC) of serum occludin level in predicting severe PHE was 0.747 (95% confidence interval CI 0.644–0.832, p < 0.001). There was a significant positive correlation between serum occludin levels and PHE volumes (partial correlation r = 0.675, p < 0.001). Multiple linear regression analysis showed that serum occludin levels remained independently associated with the PHE volumes after adjusting other confounding factors.Conclusion: The present study showed that serum occludin levels at admission were independently correlated with PHE volumes in ICH patients, which may provide a biomarker indicating PHE volume change.
- 15 June 2023
- Published by Elsevier in Brain Research
- Vol. 1816, 148464
The neuroprotective role of prolonged normobaric oxygenation applied during ischemia and in the early stage of reperfusion in cerebral ischemic rats
- 15 June 2023
- Published by Elsevier in Brain Research
- Vol. 1816, 148464
The neuroprotective role of prolonged normobaric oxygenation applied during ischemia and in the early stage of reperfusion in cerebral ischemic rats